Safety and Efficacy of LB54640 in Hypothalamic Obesity

  • Research type

    Research Study

  • Full title

    A Randomized, Placebo-Controlled, Double-Blind Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients with Hypothalamic Obesity, with an Open-Label Extension

  • IRAS ID

    1008926

  • Contact name

    LG Chem Clinical research N/A

  • Contact email

    lgclinical@lgchem.com

  • Sponsor organisation

    LG Chem, Ltd.

  • Clinicaltrials.gov Identifier

    NCT06046443

  • Research summary

    Hypothalamic obesity is a condition caused by physical damage to a part of the brain called the hypothalamus. This results in a disruption of a specific pathway in the brain, called MC4R, which helps to control appetite, energy levels, and body weight. The disrupted MC4R pathway leads to the “turning off” of an action in the brain that controls hunger and energy output (metabolism), which can contribute to increased food intake and obesity. This study is testing a potential new medication, LB54640, to see if it is safe and effective at controlling appetite and reducing weight in participants who have hypothalamic obesity by helping to activate the MC4R pathway.
    Participants will be randomly assigned to receive either LB54640 (either 200, 400, or 600 mg/day) or placebo. Placebo looks like the study drug but contains no active medication. The study drug and placebo together will be known as “study medication” . Participants will have a 75% chance of receiving active study drug and a 25% chance of receiving placebo.
    This study is "double-blinded", which means that neither the participant nor the study doctor will know which group they have been assigned to.
    The study drug will be taken by mouth once a day with water, in the morning before eating. It is to be taken at the same time each day. On study visit days, the study drug will be taken in clinic, after blood sample collection.
    Dosing will occur as follows during the treatment phase:
    Group 1: 200mg per day for 14 weeks
    Group 2: 200mg per day for 1 week, then 400mg per day for 13 weeks
    Group 3: 200mg per day for 1 week, 400mg per day for 1 week, then 600mg per day for 12 weeks
    Group 4: placebo for 14 weeks
    If participants experience any symptoms of nausea, vomiting, diarrhoea, or loose stools, the study doctor may reduce the of study drug until those symptoms resolve.
    At the end of the treatment phase, participants may be able to enter into a long-term extension phase. This will last 38 weeks.
    Lay summary of study results: Who took part?
    There were 28 participants with hypothalamic obesity, including 15 males and 13 females, between 12 and 68 years old when they joined the study. Thirteen of the participants were less than 18 years old. The participants were from the United Kingdom (10 participants) or the United States (18 participants).
    What were the results?
    One of the main goals of the study was to learn whether participants who took LB54640, which is also known as bivamelagon, lost more weight, on average, than participants who took the placebo after the first 14 weeks of treatment. To do this, researchers looked at the percent change in body mass index (BMI). BMI is a formula that compares a person’s weight to their height to estimate if the person is at a healthy weight. When someone loses weight, their BMI goes down.
    The results showed that, on average, BMI went down among participants who took bivamelagon and went up among participants who took the placebo.
    The average percent change in BMI values after 14 weeks of treatment was:
    • -2.6% among the 6 participants who took bivamelagon 200mg
    • -8.4% among the 7 participants who took bivamelagon 400mg
    • -10% among the 8 participants who took bivamelagon 600mg
    • +2.5% among the 7 participants who took the placebo
    When compared with the placebo, the average percent change in BMI dropped by 5.2% more with bivamelagon 200mg, 11% more with bivamelagon 400mg, and 12.6% more with bivamelagon 600mg.
    The other main goal of the study was to learn about the safety of bivamelagon as a treatment for hypothalamic obesity. To do this, study doctors looked at any new or worsening health issues the participants had after they started study drug. In particular, the doctors looked at health issues that they thought might be related to study drug. These related health issues are called adverse reactions.
    Some adverse reactions are considered “serious”. Examples of serious adverse reactions are those that are life-threatening, have long-term complications, or need hospital care for treatment.
    During the study, there was 1 serious adverse reaction to study drug: 1 participant who took bivamelagon 400mg during the first 14 weeks had blood in their stool.
    Other (non-serious) adverse reactions were more common.
    During the first 14 weeks:
    • All 21 participants (100%) who took bivamelagon had non-serious adverse reactions.
    • 3 of 7 participants (43%) who took the placebo had non-serious adverse reactions.
    • The most common non-serious adverse reactions among participants who took bivamelagon (those that affected at least 15%) were nausea (15 participants [71%]), diarrhoea (10 participants [48%]), vomiting (8 participants [38%]), and belly pain and headache (4 participants [19%] each).
    • These non-serious adverse reactions happened more often with bivamelagon than with the placebo. Among participants who took the placebo, 2 (29%) had an adverse reaction of nausea, 1 (14%) had an adverse reaction of diarrhoea, and 1 (14%) had an adverse reaction of vomiting.
    There were 26 participants who took part in the 38-week long-term extension phase, and all participants took bivamelagon (up to 600mg per day, if tolerated).
    During this part of the study:
    • 21 of 26 participants (81%) had non-serious adverse reactions.
    • The most common adverse reactions were nausea and vomiting (46% each), diarrhoea (31%), and belly pain, headache, and the development of a mole on the skin (15% each).
    Two participants stopped treatment because of an adverse reaction that started in the treatment phase:
    • One participant stopped treatment with bivamelagon 400mg in the treatment phase due to a serious adverse reaction of blood in their stool.
    • One participant had a non-serious adverse reaction of eczema that started while taking the placebo in the treatment phase; the eczema continued in the extension phase, and the participant stopped treatment with bivamelagon due to this reaction.
    How has this study helped?
    The results of this study helped researchers learn about bivamelagon as a possible treatment for hypothalamic obesity.
    It is important to note that these results are from just one study. Other studies could have different results.
    This study started in June 2024 and ended in February 2026. When this summary was published (in October 2026), additional studies of bivamelagon as a treatment for hypothalamic obesity were ongoing and more studies were planned.
    Where can I learn more about this study?
    You can learn more about this study here: https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Ftrack.pstmrk.it%2F3ts%2Fclinicaltrials.gov%252F%2FNBTI%2FmHLIAQ%2FAQ%2Fcc56e8b6-bb87-4532-9024-7c30faf68b98%2F1%2FAmPBcJAxtA&data=05%7C02%7Ccambridgesouth.rec%40hra.nhs.uk%7C0862718a7be84d72158808df20705d42%7C8e1f0acad87d4f20939e36243d574267%7C0%7C0%7C639265339133169096%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=ty6rS9ssUzm9cw4T35IJttCky33LuFayTVKKzw0aX24%3D&reserved=0 (United States registry). On this website, type the study’s National Clinical Trial (NCT) number (NCT06046443) into the top search box and hit “Enter”.
    Full study title: A Randomized, Placebo-Controlled, Double-Blind Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients with Hypothalamic Obesity, with an Open-Label Extension
    Study protocol number: LG-MCCL005
    Study sponsor: Rhythm Pharmaceuticals, Inc. / Phone: +1 (857) 264-4280

  • REC name

    East of England - Cambridge South Research Ethics Committee

  • REC reference

    23/EE/0255

  • Date of REC Opinion

    19 Feb 2024

  • REC opinion

    Further Information Favourable Opinion